leading to an accumulation of 12. a provider may consider testing for cyp2d6 variants prior to starting tamoxifen for breast cancer to:1.ensure the patient will not have increased adverse drug reactions to the tamoxifen2.identify potential drug drug interactions that may occur with tamoxifen3.reduce the likelihood of therapeutic failure with tamoxifen treatment4.identify poor metabolizers of tamoxifen